Lobe Sciences Ltd.

Research Lobe Sciences Ltd. (LOBE) on Bullrun: market cap EUR 11.56M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 11.56M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025CAD 0-CAD 4.54M-CAD 1.75Mn/an/aCAD 5.99MCAD 295.68KCAD 1.56M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-28EUR 11.56Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About Lobe Sciences Ltd.

Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development of lipid technology to develop innovative treatments for orphan and rare diseases. It offers Altemia® MF, a medical food designed to manage deficiencies in sickle cel disease. Lobe Sciences Ltd. was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. The company was founded in 2018 and is headquartered in Vancouver, Canada.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Lobe Sciences Ltd.'s market cap?

Lobe Sciences Ltd.'s market capitalization is EUR 11.56M.

What does Lobe Sciences Ltd. do?

Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development of lipid technology to develop innovative treatments for orphan and rare diseases. It offers Altemia® MF, a medical food designed to manage deficiencies in sickle cel disease. Lobe Sciences Ltd. was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. The company was founded in 2018 and is headquartered in Vancouver, Canada.